Themis Medicare Ltd
Themis Medicare Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹94Cr
- +13.7% YoY
- Net profit
- ₹1Cr
- −92.9% YoY
- Margin
- 6.36%
- −3.4 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Themis Medicare Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY25 Net Revenue: Rs. 93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. 82.51 Cr in Q3 FY24 (Page 9). Q3 FY25 EBITDA: Rs. 8.53 Cr, up 5.79% YoY (Q3 FY24: Rs. 8.06 Cr).
From Themis Medicare Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY25 Net Revenue: Rs. 93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. 82.51 Cr in Q3 FY24 (Page 9).
- 9M FY25 Net Revenue: Rs. 333.81 Cr, a 17.56% YoY increase from Rs. 283.94 Cr in 9M FY24 (Page 10).
- Formulation segment growth Q3 FY25: 22% YoY (Page 9).
- Hospital Business growth Q3 FY25: over 20% YoY (Page 9).
- Trade business growth Q3 FY25: approximately 37% YoY (Page 9).
- Management outlook (Page 6): Continuous growth expected, with efforts to expand hospital business and new product launches planned for commercial launch by Q4 FY 2025-26.
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation mentions plans to enhance already built-in capacity to increase productivity (Page 6, Management Comment).
- The company highlights state-of-the-art manufacturing facilities at Haridwar (Formulations) and Hyderabad and Vapi (Synthetic APIs) with annual capacities listed.
- There is ongoing R&D investment with figures given for FY19-20 to 9M FY25 but these relate to product development rather than capex (Page 16).
- The firm is working towards commercial launches of NDDS products by Q4 FY2025-26 but this concerns pipeline timing, not plant capacity or capex (Page 6).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q3 FY25 results — key figures
| ₹ Cr | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 94 | 83 | +13.7% | 117 | -19.8% |
| Operating profit (EBITDA) | 6 | 8 | -25.8% | 17 | -65.1% |
| Operating margin | 6.36% | 9.76% | -3.4 pp | 14.64% | -8.3 pp |
| Profit before tax | 2 | 8 | -79.8% | 18 | -90.7% |
| Net profit (PAT) | 1 | 7 | -92.9% | 14 | -96.4% |
| EPS (₹) | 0.06 | 0.80 | -92.5% | 1.55 | -96.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharmaceuticals (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q3 FY25 results?
Q3 FY25 Net Revenue: Rs. 93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. 82.51 Cr in Q3 FY24 (Page 9). Q3 FY25 EBITDA: Rs. 8.53 Cr, up 5.79% YoY (Q3 FY24: Rs. 8.06 Cr).
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Is Themis Medicare Ltd planning capital expenditure?
The presentation mentions plans to enhance already built-in capacity to increase productivity (Page 6, Management Comment).
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.